Clinical analysis of 49 cases of esthesioneuroblastoma.
- Author:
Mingfeng MAO
1
;
Rongguang WANG
1
;
Hongtian WANG
1
;
Xinxin ZHANG
1
;
Lei CHEN
2
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Combined Modality Therapy; Esthesioneuroblastoma, Olfactory; diagnosis; therapy; Female; Humans; Male; Middle Aged; Nasal Cavity; Nose Neoplasms; diagnosis; therapy; Prognosis; Retrospective Studies; Young Adult
- From: Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2014;49(3):210-213
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the optimal treatment and prognostic factors of esthesioneuroblastoma (ENB).
METHODForty-nine cases of ENB, received therapies in Chinese people liberation army general hospital from October 2004 to June 2013, were reviewed retrospectively. The therapeutical strategies and prognostic factors were analyzed using the Kaplan-Meier method. Efficacy of different therapeutical strategies was compared.
RESULTThe 5-year overall survival (OS) in the group was 63.8%. The 5-year OS of Kadish stage A, B, C were 90.0%, 77.1%, 32.6%, respectively, with significant difference (χ(2) = 7.379, P = 0.03). The 5-year OS of the patients treated by surgery and radiotherapy, chemoradiotherapy, surgery with chemoradiotherapy were 68.6%, 0, 92.3%, respectively, with significant difference (χ(2) = 8.140, P = 0.02). The 5-year OS of the patients with transnasal endoscopic resection (or combined with transcranial resection) and lateral rhinotomy ( or combined with transcranial resection) were 63.7%, 50.0%, respectively, which had no significant difference (χ(2) = 3.818, P = 0.05).
CONCLUSIONSENB has a relatively good prognosis in head and neck malignancies, the prognosis is associated with clinical stages and treatment approaches. Transnasal endoscopic surgery based multimodality is the preferable choice.
